ArticleBMC health services research2025
Diagnostic and analytic performance of four point-of-care hemoglobin testing devices used in routine HIV and maternity care in Uganda.
Article in BMC health services research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHemoglobin estimation (Hb) is the most requested hematology test, especially among pregnant/postnatal women and people living with HIV (PLHIV). In Uganda, several point-of-care (POC) Hb testing devices are currently used and performance may be affected by multiple factors. This study evaluated the diagnostic and analytic performance of four Hb POC devices.
methodsDuring October 2021-April 2022, four POC Hb devices (HemoCue Hb 301, DiaSpect Tm, Hemo Control, and VERI-Q Red) were evaluated against the Beckman Coulter as gold standard at four sites: Rakai Health Sciences Program clinic/Kalisizo General Hospital, Mbarara Municipal Council Health Center IV, Mpigi Health Center IV, and Atutur Hospital. Adult, consented participants aged ≥ 18 years, provided 4 mL of venous blood for concurrent Hb testing across the POC Hb devices. Anemia classification followed World Health Organization guidelines: <11.0 g/dl for pregnant women, < 12.0 g/dl for non-pregnant adult women, and < 13.0 g/dl for adult men. The Bland-Altman method was used to assess the agreement of Hb results (mean difference, standard deviation of differences, and limits of agreement). Diagnostic accuracy parameters (sensitivity, specificity, positive predictive value, negative predictive value, and accuracy) were calculated to evaluate the performance of each device compared to the reference machine.
resultsA total of 768 participants (192 from each site), comprising equal numbers of PLHIV and pregnant/postnatal women were recruited. Participants' mean (SD) Hb values were 12.1 (± 2.2) g/dl. There were strong positive correlations (all r ≥ 0.9) between each POC Hb device and the Beckman Coulter. The mean difference between POC Hb devices and Coulter readings across sites was 0.06 for the HemoCue Hb 301, 0.16 for VERI-Q Red, 0.35 for Hemo Control, and 0.57 for Diaspect Tm, with the Diaspect Tm showing the broadest limits of agreement (-0.76,1.91). The DiaSpect Tm, Hemo Control, HemoCue Hb 301 and VERI-Q Red were at least 94% (79%), 88% (87%), 77% (91%) and 75% (76%) sensitive (specific), respectively, across the study sites.
conclusionAll devices demonstrated clinically acceptable performance (within ± 1 g/dL of the reference hemoglobin), with the HemoCue Hb 301, DiaSpect Tm and Hemo Control performing most comparable to the standard, suggesting potential for interchangeable use.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.